Bayer Raises Earnings Outlook on Pharma Recovery
By Adria Calatayud
Bayer raised its full-year earnings guidance, citing a recovery in its pharmaceutical arm after strong demand for key drugs allowed the group to offset market pressures at its agricultural and consumer-health divisions.
The German group said Tuesday that it now expects full-year earnings before interest, taxes, depreciation and amortization to range from 9.8 billion to 10.3 billion euros ($10.96 billion-$11.52 billion), excluding the effect of currency changes. It had previously forecast a result between 9.6 billion and 10.1 billion euros.
The outlook upgrade was driven by expectations of higher profitability at Bayer's pharma division. Bayer said the division entered a new cycle with growth at the top and bottom lines driven by its Nubeqa prostate cancer drug and its Kerendia kidney medicine.
Overall, the group reported third-quarter sales of 10.05 billion euros, up 4.1% on year. Analysts expected quarterly sales of 9.93 billion euros, according to consensus estimates compiled by Vara Research.
The company reported a narrowed quarterly net loss of 672 million euros compared with a loss of 963 million euros, as it was hit by impairment charges and litigation expenses. Excluding exceptional items, Ebitda rose 6.9% to 1.615 billion euros.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
November 03, 2026 02:10 ET (07:10 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
This Once-Hot AI Stock Now Looks Deeply Undervalued
The 10 Best Companies to Invest in Now
3 of the Best Dividend Stocks to Own
United States